Glaukos Corporation
Business Overview: Glaukos Corporation (NYSE: GKOS)
Executive Summary
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company that pioneered the Micro-Invasive Glaucoma Surgery (MIGS) category and has since expanded into corneal health and retinal disease. Headquartered in San Clemente, California, Glaukos effectively created the modern MIGS device market with its iStent platform and has used that first-mover position to build a broader pipeline of implantable and drug-delivery technologies for chronic eye disease.
Its revenue is concentrated in ophthalmic surgeons and clinics, selling devices and bio-activated therapies that treat conditions (glaucoma, keratoconus) with limited good treatment alternatives.
1. Core Business Model & How They Work
Glaukos sells implantable micro-devices and bio-activated therapies rather than a typical consumables/capital-equipment model. Once a surgeon is trained and a device is reimbursed, it becomes part of a repeatable, procedure-based revenue stream.
[ Device/Therapy R&D ] ➡️ [ FDA Approval / Clearance ] ➡️ [ Surgeon Training ] ➡️ [ Procedure Adoption ] ➡️ [ Reimbursement Codes Secured ] ➡️ [ Recurring Procedure Volume ]2. Product Portfolio
| Platform | Category | Purpose | Why It Matters |
|---|---|---|---|
| iStent / iStent inject W / iStent infinite | Glaucoma (MIGS) | Micro-bypass stents that lower intraocular pressure | The original MIGS devices; ~79% of FY2024 net sales combined with iDose TR |
| iDose TR | Glaucoma | Intracameral implant delivering sustained travoprost | FDA-approved Dec. 2023; commercialization began 2024 — a continuous drug-delivery alternative to daily eye drops |
| iLink (KXL System + Photrexa) | Corneal health | Corneal cross-linking for keratoconus | ~21% of FY2024 net sales; Epioxa (epi-on) NDA submitted Dec. 2024 for an easier, non-epithelium-removing version |
| iLution | Anterior segment (pipeline) | Eyelid-applied transdermal creams for dry eye, presbyopia, glaucoma, Demodex blepharitis | Early-stage pipeline; could extend Glaukos beyond implantable devices into topical therapeutics |
| Retinal XR | Retina (pipeline) | Sustained-release implants for AMD, DME, RVO | First-in-human trial started Dec. 2023; optionality in a large, underserved disease category |
3. Competitive Landscape
- Glaucoma MIGS: Alcon (which acquired Ivantis), Sight Sciences, and New World Medical compete directly for MIGS procedure volume.
- Glaucoma drugs: AbbVie's topical glaucoma franchise competes for the same patients Glaukos is trying to move onto sustained-release implants like iDose TR.
- Corneal cross-linking: compounding pharmacies and other crosslinking providers (e.g., PeschkeTrade GmbH) offer lower-cost, less-regulated alternatives.
- Anterior/posterior pipeline: Glaukos's longer-term pipeline bets compete against much larger players — AbbVie, Alcon, Johnson & Johnson, Novartis, Genentech/Roche, Regeneron, and Bayer — in therapeutic areas where Glaukos has no approved product yet.
4. Strategic Strengths & Risks
Strengths
- Category creator: Glaukos effectively invented the MIGS device category with iStent, giving it incumbency and surgeon familiarity advantages.
- Deep IP position: more than 500 patents and applications, with issued patents expiring between 2025 and 2043.
- Diversifying pipeline: corneal health and retina programs reduce dependence on glaucoma device reimbursement dynamics alone.
Risks
- Reimbursement dependence: Medicare coverage for iStent infinite and iDose TR hinges on MAC (Medicare Administrative Contractor) coverage decisions and billing codes, plus Medicaid rebate/340B pricing obligations.
- Regulatory classification risk: drug-device combination classification for iDose TR could complicate or delay approvals; the EU could reclassify its corneal cross-linking therapy as a drug rather than a device.
- Single-site manufacturing concentration: iStent and iDose manufacturing is concentrated at one San Clemente, California campus — a real operational single point of failure.
- Trade policy exposure: potential tariffs or export controls on materials, though management describes current exposure as limited.
5. Financial Overview
| Metric | Glaukos Profile | Strategic Context |
|---|---|---|
| Revenue Mix (FY2024) | ~79% iStent family/iDose TR; ~21% iLink; retina/iLution $0 | Still a glaucoma-device company today; corneal and retina are the optionality |
| Geographic Mix | ~70% U.S., ~30% international | Reimbursement-driven U.S. concentration |
| Customer Concentration | No customer/distributor >10% of sales | Broad surgeon/clinic base, not a few large accounts |
| R&D | ~12 active pipeline programs | Company states R&D/clinical spend is expected to keep rising |
6. Summary Conclusion
Glaukos's moat rests on having created and still leading a device category (MIGS) that is hard to replicate without deep IP and FDA-cleared clinical data, reinforced by a growing bio-activated therapy franchise in corneal health. The company's near-term fortunes still ride heavily on continued favorable reimbursement for iStent and iDose TR, while its longer-term upside depends on whether iLution and Retinal XR can turn Glaukos from a glaucoma-device specialist into a broader ophthalmic therapeutics platform.